title: Forecasting cholesterol management--end of the statin gold rush?
authors.forename: Brian K
authors.initials: BK
authors.lastname: Crownover
authors.forename: Frederic R
authors.initials: FR
authors.lastname: Curtiss
mesh_terms: D000924:Anticholesteremic Agents / Q000191:economics* / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000191:economics* / Q000209:etiology / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004358:Drug Therapy / Q000639:trends; D016568:Drugs, Generic / Q000191:economics / Q000627:therapeutic use; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000191:economics*; D005544:Forecasting; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D008329:Managed Care Programs; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D016568:Drugs, Generic; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors